Sermorelin acetate is sermorelin. The acetate is a salt — the counter-ion a peptide is packaged with so it stays stable as a powder — and it is not a second drug, a stronger version, or a different generation of anything. If a seller offers you “sermorelin acetate” and another offers “sermorelin,” they are offering the same molecule.
The interesting part is not the chemistry. It is that the two names live in completely different places, and that the number printed beside them does not mean a fixed thing.
The literature does not use the name at all
On September 14, 2026, PubMed returned zero papers with the phrase “sermorelin acetate” anywhere in a title or abstract — the database volunteers a warning that it could not find the phrase [1]. Not a rare term. Zero.
That is only worth saying because the same search works for everything else. “Leuprolide acetate” returns 1,301 papers, “glatiramer acetate” 2,173, and “octreotide acetate” 282. The construction indexes perfectly well; researchers simply never write it about this drug. They write “sermorelin,” which appears in 24 titles and abstracts and is indexed on 332 records overall.
There is a trap in checking this yourself. Search sermorelin acetate without quotation marks and PubMed returns 332 — the identical count as plain sermorelin, because it maps both to the same subject heading. It looks like the phrase is everywhere. Put quotation marks around it and the number is zero. The same pattern holds in chemical databases: PubChem carries one compound, the free base, and returns nothing for the acetate as a separate entry [2].
Where the name does live is the pharmacy shelf
Everywhere a product is sold rather than studied, the acetate is named. Levers Health lists its ingredient as “Compounded Sermorelin Acetate, 1mg/ml,” with a separate line for three states where it is 3mg/ml [3]. The FDA’s own October 2024 briefing to its compounding advisory committee surveyed pharmacy websites and quoted their catalog entries back verbatim — “ipamorelin/sermorelin acetate (lyo) 15/18 mg vial” and a 15/9 mg version — while the same document calls the drug itself simply sermorelin [4].
So the split is clean: the scientific name is sermorelin, the dispensing name is sermorelin acetate, and a page using one instead of the other tells you which world it came from rather than what is in the vial. That is also why the description of what the drug is does not change between them.
The milligrams are the part that is genuinely unsettled
A salt weighs more than the base it carries, so a vial labeled “9 mg” delivers 9 mg of drug only if the label means the base. Regulators handle this explicitly. When Geref was approved, the FDA recorded its strength as “EQ 0.05 MG BASE/AMP” and later “EQ 0.5 MG BASE/VIAL” and “EQ 1 MG BASE/VIAL” — equivalent to that much base, stated that way on purpose [5].
And the convention is not uniform even among approved drugs, which is what makes this a real ambiguity rather than a technicality. Sandostatin is recorded as “EQ 1 MG BASE/ML” and Trelstar as “EQ 11.25 MG BASE/VIAL,” while Lupron Depot is simply “3.75MG/VIAL” and Copaxone “20MG/ML” — the weight of the salt itself [5]. Two approved acetate peptides, two different meanings of the same unit.
No compounded sermorelin page reviewed here resolves it. Sellers state a concentration and a vial size and stop; none says whether the figure is base or salt. It is not possible to convert between them from outside either, because peptide acetate salts carry a variable acetate content rather than a fixed ratio. The honest position is that the number is unstated, not that it is secretly higher or lower.
How far apart the labels actually are
Before worrying about a salt correction, it is worth seeing the spread in the labels themselves. Reading the sellers covered here on September 14, 2026, a stated vial ran from 6 mg to 20 mg and a stated dose from 200 mcg to 1,000 mcg. One page sits outside that range entirely: Ivy Rx advertises its injection as “1000mg per vial” [6], which is two orders of magnitude above every other vial on the list and reads like a microgram figure printed in milligrams.
Against that, a salt-versus-base difference is the smaller problem. Both point the same way: a milligram figure on a compounded sermorelin page is not a quantity you can compare across sellers, which is why the dose question has to be answered in what you inject rather than in what the vial says, and why the certificate of analysis is the document that settles content.
What to do with this
Nothing, if you are choosing between two sellers who both say “sermorelin” and both say “acetate.” The name carries no information about quality, potency or source, and treating the acetate as a premium form is reading a packaging fact as a clinical one.
Something, if you are comparing vial sizes or working out cost per milligram. Ask the prescriber or the pharmacy whether the stated strength is the peptide or the salt, and ask for the certificate of analysis, which reports content directly. Those two questions belong on the list you take into the consultation, and the regulatory side of the name — why every US sermorelin is compounded in the first place — is a separate question with a documented answer.